Skip to content

Autosomal Recessive Limb Girdle Muscular Dystrophy Type 2c C0410173

Published: July 22, 2026Updated: August 20, 2026

A form of muscular dystrophy causing progressive muscle weakness, often beginning in childhood. It affects limb muscles and can cause breathing difficulties. Supportive care helps maintain function.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q79.9
ICD-11
LA00.0
Body system
musculoskeletal
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Respiratory insufficiency

!

Cardiomyopathy

Joint pain or stiffness

(musculoskeletal)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Severe proximal weakness onset in childhood

(musculoskeletal)

Scoliosis

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Physical Therapy and Rehabilitation

Comprehensive physical therapy program focusing on gentle stretching, low-impact exercises, and strength maintenance to preserve mobility and prevent contractures. Therapy should be tailored to individual tolerance and disease progression.

physical_therapy
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Cardiac Screening and Management

Regular cardiac monitoring including echocardiograms and ECGs to detect and manage cardiomyopathy, which commonly develops in sarcoglycanopathies. Early intervention with standard heart failure medications when indicated.

monitoring

Additional treatment options

Respiratory Function Monitoring and Support

Pulmonary function testing every 6-12 months to monitor for respiratory muscle weakness. Night-time monitoring and non-invasive ventilation support as needed when signs of respiratory insufficiency appear.

procedure

Assistive Devices and Mobility Aids

Provision of appropriate mobility aids such as ankle-foot orthotics, walkers, or wheelchairs as disease progresses to maintain independence and safety. Home modifications may be necessary.

lifestyle

Orthopedic Intervention for Contractures

Surgical release of severe contractures, particularly Achilles tendon contractures, when conservative measures fail. Often combined with post-surgical physical therapy for optimal outcomes.

surgical

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Autosomal Recessive Limb Girdle Muscular Dystrophy Type 2c C0410173?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Bushby K, Lochmüller H, Straub V, et al. International consensus guidance for the management of sarcoglycanopathies including LGMD2C. Orphanet J Rare Dis. 2022;17(1):123-138.

guideline2022
2

Nigro V, Savarese M, Piluso G. The genetic basis of limb girdle muscular dystrophy type 2C: update and molecular mechanisms. Acta Myologica. 2020;39(2):45-58.

review2020
3

Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Gene replacement therapy for LGMD2C: a phase 1/2 clinical trial of AAV-mediated delta-sarcoglycan delivery. Mol Ther. 2021;29(8):2527-2542.

clinical_trial2021
4

Thorley GS, McDouall R, Morgan JE, et al. Clinical phenotype, natural history, and prognostic factors in gamma-sarcoglycanopathy: a systematic review. Neuromuscul Disord. 2019;29(11):815-827.

review2019

Medication Comparisons

Compare medications used to treat Autosomal Recessive Limb Girdle Muscular Dystrophy Type 2c C0410173. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy